Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Novel prophylactic and therapeutic vaccine against tuberculosis.

Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Inoue Y, Matsumoto M, McMurray DN, Dela Cruz EC, Tan EV, Abalos RM, Burgos JA, Saunderson P, Sakatani M.

Vaccine. 2009 May 26;27(25-26):3267-70. doi: 10.1016/j.vaccine.2009.01.064. Epub 2009 Feb 5.

PMID:
19200841
2.

Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing.

Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11293-8. doi: 10.1073/pnas.0800965105. Epub 2008 Aug 11.

3.

Impact of HIV on novel therapies for tuberculosis control.

Sánchez MS, Lloyd-Smith JO, Porco TC, Williams BG, Borgdorff MW, Mansoer J, Salomon JA, Getz WM.

AIDS. 2008 May 11;22(8):963-72. doi: 10.1097/QAD.0b013e3282f7cb4b.

PMID:
18453856
4.

Eliminating human tuberculosis in the twenty-first century.

Dye C, Williams BG.

J R Soc Interface. 2008 Jun 6;5(23):653-62.

5.

New tuberculosis therapeutics: a growing pipeline.

Spigelman MK.

J Infect Dis. 2007 Aug 15;196 Suppl 1:S28-34. Review.

PMID:
17624823
6.

Current strategies for identifying and validating targets for new treatment-shortening drugs for TB.

Williams KJ, Duncan K.

Curr Mol Med. 2007 May;7(3):297-307. Review.

PMID:
17504114
7.

Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.

Moulton LH, Golub JE, Durovni B, Cavalcante SC, Pacheco AG, Saraceni V, King B, Chaisson RE.

Clin Trials. 2007;4(2):190-9.

PMID:
17456522
8.

Reducing the global burden of tuberculosis: the contribution of improved diagnostics.

Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, Aledort JE, Hillborne L, Rafael ME, Girosi F, Dye C.

Nature. 2006 Nov 23;444 Suppl 1:49-57. No abstract available.

PMID:
17159894
9.

Prospects for advancing tuberculosis control efforts through novel therapies.

Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sánchez MS, Porco TC, Borgdorff MW.

PLoS Med. 2006 Aug;3(8):e273.

10.

Cost-effectiveness of treating multidrug-resistant tuberculosis.

Resch SC, Salomon JA, Murray M, Weinstein MC.

PLoS Med. 2006 Jul;3(7):e241.

11.

Advances in tuberculosis vaccine strategies.

Skeiky YA, Sadoff JC.

Nat Rev Microbiol. 2006 Jun;4(6):469-76. Review.

PMID:
16710326
12.

Targets for global tuberculosis control.

Dye C, Maher D, Weil D, Espinal M, Raviglione M.

Int J Tuberc Lung Dis. 2006 Apr;10(4):460-2. Review.

PMID:
16602414
13.

WHO's new Stop TB Strategy.

Raviglione MC, Uplekar MW.

Lancet. 2006 Mar 18;367(9514):952-5. No abstract available.

PMID:
16546550
14.

The development and impact of tuberculosis vaccines.

Young D, Dye C.

Cell. 2006 Feb 24;124(4):683-7.

15.

Potential public health impact of new tuberculosis vaccines.

Ziv E, Daley CL, Blower S.

Emerg Infect Dis. 2004 Sep;10(9):1529-35. Review.

16.

On treatment of tuberculosis in heterogeneous populations.

Murphy BM, Singer BH, Kirschner D.

J Theor Biol. 2003 Aug 21;223(4):391-404.

PMID:
12875819
17.

Comparing epidemic tuberculosis in demographically distinct heterogeneous populations.

Murphy BM, Singer BH, Anderson S, Kirschner D.

Math Biosci. 2002 Nov-Dec;180:161-85.

PMID:
12387922
18.

AIDS epidemic update: December 1999.

Joint United Nations Programme on HIV / AIDS UNAIDS.

AIDS Anal Afr. 2000 Feb-Mar;10(5):2.

PMID:
12322486
19.

Lifetime risks, incubation period, and serial interval of tuberculosis.

Vynnycky E, Fine PE.

Am J Epidemiol. 2000 Aug 1;152(3):247-63.

PMID:
10933272
20.

Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

Dye C, Garnett GP, Sleeman K, Williams BG.

Lancet. 1998 Dec 12;352(9144):1886-91.

PMID:
9863786

Supplemental Content

Support Center